Objective The purpose of this study was to investigate the effect of disease modifying
therapies on immune response to severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2…

Background People with MS treated with anti-CD20 therapies and fingolimod often have
attenuated responses to initial COVID-19 vaccination. However, uncertainties remain about the …

Background: Iron rims (IRs) surrounding white matter lesions (WMLs) are suggested to predict
a more severe disease course. Only small longitudinal cohorts of patients with and without …

Background and purpose Treatment persistence is the continuation of therapy over time. It
reflects a combination of treatment efficacy and tolerability. We aimed to describe real‐world …

Background Annualized relapse rate (ARR) is used as an outcome measure in multiple
sclerosis (MS) clinical trials. Previous studies demonstrated that ARR has reduced in placebo …

Background: People with multiple sclerosis (pwMS) treated with certain disease-modifying
therapies (DMTs) have attenuated IgG response following COVID-19 vaccination; however, …

Introduction Identifying accurate prognostic imaging biomarkers in multiple sclerosis (MS) is
crucial. Iron rims (IR) surrounding white matter lesions (WML) are suggested to predict a …

OBJECTIVE To determine whether brief attendance for outpatient radiological investigations
is associated with increased risk of clinically significant coronavirus disease 2019 (covid-19…

Background Relapses are a marker of disease activity and Annualized Relapse Rate (ARR)
is used as an outcome measure in MS clinical trials. ARR has reduced in placebo groups …

Background: Iron rim lesions (IRLs), white matter lesions (WMLs) accumulation and linear
brain atrophy measurements have been suggested to be important imaging biomarkers in …